FINWIRES · TerminalLIVE
FINWIRES

Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer

By

Merck (MRK) said Wednesday that Keytruda, in combination with enfortumab vedotin, has received Canadian approval for the treatment of muscle-invasive bladder cancer in adults who are ineligible for cisplatin-containing chemotherapy.

The company said that the approval from Health Canada was based on results from a phase-3 trial, which was conducted in collaboration with Pfizer (PFE) and Astellas.

Results from the trial showed that patients treated with neoadjuvant and adjuvant Keytruda in combination with enfortumab vedotin had statistically significant improvements in event-free survival and overall survival compared with radical cystectomy and pelvic lymph node dissection alone, the company said.

Price: $130.02, Change: $+2.02, Percent Change: +1.58%

Related Articles

Wire

Zeta Global Swings to Q2 Earnings, Revenue Rises; Shares Drop After Hours

Zeta Global Holdings (ZETA) reported Q2 net income late Tuesday of $8.17 million, swinging from the loss of $12.8 million a year earlier.Revenue in the three months ended June 30 rose to $442.8 million from $308.4 million a year earlier.Analysts surveyed by FactSet expected $420.6 million.The company expects Q3 revenue of $469 million to $472 million, up $10 million at the midpoint from the prior guidance of $461 million.Analysts project $461 million.Zeta boosted full-year guidance to GAAP EPS of $0.09 to $0.11 from the prior forecast of $0.02 to $0.04 on revenue of $1.811 billion to $1.824 billion, up $33 million at the midpoint from the previous projection of $1.785 billion.Analysts expect EPS of $0.04 on revenue of $1.79 billion.Zeta shares fell 6.8% in after-hours trading.

$ZETA
Wire

Voya Financial Q2 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Voya Financial (VOYA) reported Q2 adjusted net income late Tuesday of $1.51 per diluted share, down from $2.46 a year earlier.Analysts polled by FactSet expected $1.98.Revenue in the three months ended June 30 fell to $1.896 billion from $1.981 billion a year earlier.Analysts expected $1.897 billion.Voya shares fell 3.9% in after-hours trading.

$VOYA
Wire

Toast Q2 Earnings, Revenue Rise; Shares Drop After Hours

Toast (TOST) reported Q2 earnings late Tuesday of $0.26 per diluted share, up from $0.13 a year earlier.Analysts surveyed by FactSet expected $0.20.Revenue in the three months ended June 30 rose to $1.91 billion from $1.55 billion a year earlier.Analysts expected $1.87 billion.Toast shares fell 6.4% in after-hours trading.

$TOST